Solural Pharma initiates first human dosing on the SOL-924 new product formulation developed by Solural Pharma ApS. The project is being developed in partnership with an undisclosed major US partner.
- New patent acquisition agreement November 16, 2022
- New Eurasia patent December 25, 2020
- New Manufacturing Authorisation December 18, 2020
If you are interested in joining Solural Pharma ApS, we are seeking professionals, technicians and consultants with expertise within drug development. Please contact
email@example.com for more information about available positions.